US › Healthcare

vTv Therapeutics Inc (VTVT)

US · Healthcare · Biotechnology

$32.06-1.02%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$36.8M
Net profit
$24.1M
Profit YoY
+574.0%
EPS
$1.65
EPS estimate
$0.21
Net margin
65.5%

EPS came in at 1.65 against a street estimate of 0.21 — a beat of 685.7%.

Key statistics

Market cap
$127.6M
Forward P/E
0.0
P/B
1.41
Book value
$7.25
EPS (TTM)
$-0.78
52-week high
$44.00
52-week low
$14.00
50-day MA
$33.42
200-day MA
$33.27
Beta
0.29

Analyst view

Analysts rate vTv Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $54.33.

Shareholding

Insiders
38.98%
Institutions
39.66%

Largest institutional holders

FundStake
Samsara BioCapital, LLC7.58%
FMR Inc6.61%
Millennium Management LLC5.24%
Siren, L.L.C.4.14%
Baker Bros Advisors LP3.77%
Trails Edge Capital Partners, LP3.54%
Vanguard Capital Management, LLC2.77%
Geode Capital Management, LLC0.83%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for vTv Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.